The role of β-blockers in the management of hypertension

An Asian perspective

B. Tomlinson, J. J. Dalal, J. Huang, L. P. Low, Chang Gyu Park, A. R. Rahman, E. B. Reyes, A. A. Soenarta, A. Heagerty, F. Follath

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Following publication of the National Institute of Clinical Excellence (NICE) Guidelines in 2006, the use of β-blockers as first-line therapy in hypertension has been somewhat controversial. However, a recent reappraisal of the European Society of Hypertension guidelines highlights that these agents exhibit similar BP lowering efficacy to other classes of agents, prompting a re-examination of the utility of these agents in various patient populations. The authors felt that it is important to address this controversy and provide an Asian perspective on the place of β-blockers in current clinical practice and the benefits of β-blockade in selected patient populations. In addition to their use as a potential first-line therapy in uncomplicated hypertension, β-blockers have a particular role in patients with hypertension and comorbidities such as heart failure or coronary artery disease, including those who had a myocardial infarction. One advantage which β-blockers offer is the additional protective effects in patients with prior cardiovascular events. Some of the disadvantages attributed to β-blockers appear more related to the older drugs in this class and further appraisal of the efficacy and safety profile of newer β-blockers will lend support to the current guideline recommendations in Asian countries and encourage increased appropriate use of β-blockade in current clinical practice within Asia.

Original languageEnglish
Pages (from-to)1021-1033
Number of pages13
JournalCurrent Medical Research and Opinion
Volume27
Issue number5
DOIs
Publication statusPublished - 2011 May 1

Fingerprint

Hypertension
Guidelines
Population
Publications
Comorbidity
Coronary Artery Disease
Heart Failure
Myocardial Infarction
Safety
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adrenergic β-antagonists
  • Asia
  • Guidelines
  • Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The role of β-blockers in the management of hypertension : An Asian perspective. / Tomlinson, B.; Dalal, J. J.; Huang, J.; Low, L. P.; Park, Chang Gyu; Rahman, A. R.; Reyes, E. B.; Soenarta, A. A.; Heagerty, A.; Follath, F.

In: Current Medical Research and Opinion, Vol. 27, No. 5, 01.05.2011, p. 1021-1033.

Research output: Contribution to journalReview article

Tomlinson, B, Dalal, JJ, Huang, J, Low, LP, Park, CG, Rahman, AR, Reyes, EB, Soenarta, AA, Heagerty, A & Follath, F 2011, 'The role of β-blockers in the management of hypertension: An Asian perspective', Current Medical Research and Opinion, vol. 27, no. 5, pp. 1021-1033. https://doi.org/10.1185/03007995.2011.562884
Tomlinson, B. ; Dalal, J. J. ; Huang, J. ; Low, L. P. ; Park, Chang Gyu ; Rahman, A. R. ; Reyes, E. B. ; Soenarta, A. A. ; Heagerty, A. ; Follath, F. / The role of β-blockers in the management of hypertension : An Asian perspective. In: Current Medical Research and Opinion. 2011 ; Vol. 27, No. 5. pp. 1021-1033.
@article{a867c6e4050b4f11a280ecb4b3a23d9c,
title = "The role of β-blockers in the management of hypertension: An Asian perspective",
abstract = "Following publication of the National Institute of Clinical Excellence (NICE) Guidelines in 2006, the use of β-blockers as first-line therapy in hypertension has been somewhat controversial. However, a recent reappraisal of the European Society of Hypertension guidelines highlights that these agents exhibit similar BP lowering efficacy to other classes of agents, prompting a re-examination of the utility of these agents in various patient populations. The authors felt that it is important to address this controversy and provide an Asian perspective on the place of β-blockers in current clinical practice and the benefits of β-blockade in selected patient populations. In addition to their use as a potential first-line therapy in uncomplicated hypertension, β-blockers have a particular role in patients with hypertension and comorbidities such as heart failure or coronary artery disease, including those who had a myocardial infarction. One advantage which β-blockers offer is the additional protective effects in patients with prior cardiovascular events. Some of the disadvantages attributed to β-blockers appear more related to the older drugs in this class and further appraisal of the efficacy and safety profile of newer β-blockers will lend support to the current guideline recommendations in Asian countries and encourage increased appropriate use of β-blockade in current clinical practice within Asia.",
keywords = "Adrenergic β-antagonists, Asia, Guidelines, Hypertension",
author = "B. Tomlinson and Dalal, {J. J.} and J. Huang and Low, {L. P.} and Park, {Chang Gyu} and Rahman, {A. R.} and Reyes, {E. B.} and Soenarta, {A. A.} and A. Heagerty and F. Follath",
year = "2011",
month = "5",
day = "1",
doi = "10.1185/03007995.2011.562884",
language = "English",
volume = "27",
pages = "1021--1033",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - The role of β-blockers in the management of hypertension

T2 - An Asian perspective

AU - Tomlinson, B.

AU - Dalal, J. J.

AU - Huang, J.

AU - Low, L. P.

AU - Park, Chang Gyu

AU - Rahman, A. R.

AU - Reyes, E. B.

AU - Soenarta, A. A.

AU - Heagerty, A.

AU - Follath, F.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Following publication of the National Institute of Clinical Excellence (NICE) Guidelines in 2006, the use of β-blockers as first-line therapy in hypertension has been somewhat controversial. However, a recent reappraisal of the European Society of Hypertension guidelines highlights that these agents exhibit similar BP lowering efficacy to other classes of agents, prompting a re-examination of the utility of these agents in various patient populations. The authors felt that it is important to address this controversy and provide an Asian perspective on the place of β-blockers in current clinical practice and the benefits of β-blockade in selected patient populations. In addition to their use as a potential first-line therapy in uncomplicated hypertension, β-blockers have a particular role in patients with hypertension and comorbidities such as heart failure or coronary artery disease, including those who had a myocardial infarction. One advantage which β-blockers offer is the additional protective effects in patients with prior cardiovascular events. Some of the disadvantages attributed to β-blockers appear more related to the older drugs in this class and further appraisal of the efficacy and safety profile of newer β-blockers will lend support to the current guideline recommendations in Asian countries and encourage increased appropriate use of β-blockade in current clinical practice within Asia.

AB - Following publication of the National Institute of Clinical Excellence (NICE) Guidelines in 2006, the use of β-blockers as first-line therapy in hypertension has been somewhat controversial. However, a recent reappraisal of the European Society of Hypertension guidelines highlights that these agents exhibit similar BP lowering efficacy to other classes of agents, prompting a re-examination of the utility of these agents in various patient populations. The authors felt that it is important to address this controversy and provide an Asian perspective on the place of β-blockers in current clinical practice and the benefits of β-blockade in selected patient populations. In addition to their use as a potential first-line therapy in uncomplicated hypertension, β-blockers have a particular role in patients with hypertension and comorbidities such as heart failure or coronary artery disease, including those who had a myocardial infarction. One advantage which β-blockers offer is the additional protective effects in patients with prior cardiovascular events. Some of the disadvantages attributed to β-blockers appear more related to the older drugs in this class and further appraisal of the efficacy and safety profile of newer β-blockers will lend support to the current guideline recommendations in Asian countries and encourage increased appropriate use of β-blockade in current clinical practice within Asia.

KW - Adrenergic β-antagonists

KW - Asia

KW - Guidelines

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=79954506127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954506127&partnerID=8YFLogxK

U2 - 10.1185/03007995.2011.562884

DO - 10.1185/03007995.2011.562884

M3 - Review article

VL - 27

SP - 1021

EP - 1033

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 5

ER -